Clinical Trial Update: SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Faslodex (fulvestrant) after aromatase inhibitor failure in advanced breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED